MANSFIELD, Mass.-- (BUSINESS WIRE)-- Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the Solitaire™ FR Thrombectomy for Acute Revascularization ...
“Solitaire FR provides physicians with another important tool for treating this potentially fatal and often debilitating condition.” The Solitaire FR device received CE Mark approval in Europe and has ...
March 6, 2012 — The US Food and Drug Administration (FDA) has granted approval for a new clot retrieval system, the Solitaire Flow Restoration (FR) device (Covidien), the company has announced. The ...
Two-Year Clinical Study Supports Safety and Efficacy of Covidien Solitaire™ FR Revascularization Dev
STAR Study Reviews Device Use in Blood Clot Removal Treatment for Patients Experiencing Acute Ischemic Stroke Covidien's Solitaire FR device is designed to restore blood flow in patients experiencing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results